Amphista Therapeutics operates as a biopharmaceutical company.
Amphista Therapeutics operates as a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body's natural processes to selectively and efficiently degrade and remove disease causing proteins.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 13, 2022 | Series B | — | 1 |
Dementia Discovery Fund
|
— | Detail |
| Mar 17, 2021 | Series B | $53M | 6 |
Forbion Capital Partners
|
— | Detail |
| Apr 7, 2020 | Series A | $7.50M | 4 |
Advent Life Sciences
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Dementia Discovery Fund
|
Yes | Series B |
Forbion Capital Partners
|
Yes | Series B |
|
|
Yes | Series B |
Advent Life Sciences
|
— | Series B |
BioMotiv
|
— | Series B |
Eli Lilly & Company Foundation
|
— | Series B |
Novartis Venture Fund
|
— | Series B |
European Investment Fund
|
— | Series A |
Scottish Investment Bank
|
— | Series A |